These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 27936344)

  • 21. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
    Cunningham AL; Lal H; Kovac M; Chlibek R; Hwang SJ; Díez-Domingo J; Godeaux O; Levin MJ; McElhaney JE; Puig-Barberà J; Vanden Abeele C; Vesikari T; Watanabe D; Zahaf T; Ahonen A; Athan E; Barba-Gomez JF; Campora L; de Looze F; Downey HJ; Ghesquiere W; Gorfinkel I; Korhonen T; Leung E; McNeil SA; Oostvogels L; Rombo L; Smetana J; Weckx L; Yeo W; Heineman TC;
    N Engl J Med; 2016 Sep; 375(11):1019-32. PubMed ID: 27626517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial.
    Maréchal C; Lal H; Poder A; Ferguson M; Enweonye I; Heineman TC; Hervé C; Rheault P; Talli J; Wauters D; Oostvogels L
    Vaccine; 2018 Jul; 36(29):4278-4286. PubMed ID: 29903674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older.
    Cunningham AL; Heineman TC; Lal H; Godeaux O; Chlibek R; Hwang SJ; McElhaney JE; Vesikari T; Andrews C; Choi WS; Esen M; Ikematsu H; Choma MK; Pauksens K; Ravault S; Salaun B; Schwarz TF; Smetana J; Abeele CV; Van den Steen P; Vastiau I; Weckx LY; Levin MJ;
    J Infect Dis; 2018 May; 217(11):1750-1760. PubMed ID: 29529222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study.
    Chlibek R; Smetana J; Pauksens K; Rombo L; Van den Hoek JA; Richardus JH; Plassmann G; Schwarz TF; Ledent E; Heineman TC
    Vaccine; 2014 Mar; 32(15):1745-53. PubMed ID: 24508036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules.
    Vesikari T; Hardt R; Rümke HC; Icardi G; Montero J; Thomas S; Sadorge C; Fiquet A
    Hum Vaccin Immunother; 2013 Apr; 9(4):858-64. PubMed ID: 23319176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and Safety of a Live Attenuated Zoster Vaccine (ZOSTAVAX™) in Korean Adults.
    Choi WS; Choi JH; Choi JY; Eom JS; Kim SI; Pai H; Peck KR; Sohn JW; Cheong HJ
    J Korean Med Sci; 2016 Jan; 31(1):13-7. PubMed ID: 26770032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study.
    Berkowitz EM; Moyle G; Stellbrink HJ; Schürmann D; Kegg S; Stoll M; El Idrissi M; Oostvogels L; Heineman TC;
    J Infect Dis; 2015 Apr; 211(8):1279-87. PubMed ID: 25371534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial.
    Beals CR; Railkar RA; Schaeffer AK; Levin Y; Kochba E; Meyer BK; Evans RK; Sheldon EA; Lasseter K; Lang N; Weinberg A; Canniff J; Levin MJ
    Lancet Infect Dis; 2016 Aug; 16(8):915-22. PubMed ID: 27061887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine.
    James SF; Chahine EB; Sucher AJ; Hanna C
    Ann Pharmacother; 2018 Jul; 52(7):673-680. PubMed ID: 29457489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax® in healthy adults aged 50 years and older.
    Choi WS; Choi JH; Jung DS; Choi HJ; Kim YS; Lee J; Jang HC; Shin EC; Park JS; Kim H; Cheong HJ
    Vaccine; 2019 Jun; 37(27):3605-3610. PubMed ID: 31122860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.
    Gorse GJ; Falsey AR; Johnson CM; Morrison D; Fried DL; Ervin JE; Greenberg DP; Ozol-Godfrey A; Landolfi V; Tsang PH
    Vaccine; 2013 Dec; 31(50):6034-40. PubMed ID: 24055306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.
    Curran D; Van Oorschot D; Varghese L; Oostvogels L; Mrkvan T; Colindres R; von Krempelhuber A; Anastassopoulou A
    Hum Vaccin Immunother; 2017 Oct; 13(10):2213-2221. PubMed ID: 28708959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age.
    Vermeulen JN; Lange JM; Tyring SK; Peters PH; Nunez M; Poland G; Levin MJ; Freeman C; Chalikonda I; Li J; Smith JG; Caulfield MJ; Stek JE; Chan IS; Vessey R; Schödel FP; Annunziato PW; Schlienger K; Silber JL
    Vaccine; 2012 Jan; 30(5):904-10. PubMed ID: 22154769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial.
    Vink P; Delgado Mingorance I; Maximiano Alonso C; Rubio-Viqueira B; Jung KH; Rodriguez Moreno JF; Grande E; Marrupe Gonzalez D; Lowndes S; Puente J; Kristeleit H; Farrugia D; McNeil SA; Campora L; Di Paolo E; El Idrissi M; Godeaux O; López-Fauqued M; Salaun B; Heineman TC; Oostvogels L;
    Cancer; 2019 Apr; 125(8):1301-1312. PubMed ID: 30707761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.
    Kerzner B; Murray AV; Cheng E; Ifle R; Harvey PR; Tomlinson M; Barben JL; Rarrick K; Stek JE; Chung MO; Schödel FP; Wang WW; Xu J; Chan IS; Silber JL; Schlienger K
    J Am Geriatr Soc; 2007 Oct; 55(10):1499-507. PubMed ID: 17908055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors.
    Källmark H; Bergström T; Nagel J; Gullstrand B; Einarsson JT; Bengtsson AA; Kapetanovic MC
    Rheumatology (Oxford); 2024 Jul; 63(7):2024-2033. PubMed ID: 37851412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine.
    Fochesato M; Dendouga N; Boxus M
    Hum Vaccin Immunother; 2016 Aug; 12(8):2092-2095. PubMed ID: 26933767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age.
    Blatter MM; Klein NP; Shepard JS; Leonardi M; Shapiro S; Schear M; Mufson MA; Martin JM; Varman M; Grogg S; London A; Cambron P; Douha M; Nicholson O; da Costa C; Innis BL
    Pediatr Infect Dis J; 2012 Aug; 31(8):e133-40. PubMed ID: 22622699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials.
    Kovac M; Lal H; Cunningham AL; Levin MJ; Johnson RW; Campora L; Volpi A; Heineman TC;
    Vaccine; 2018 Mar; 36(12):1537-1541. PubMed ID: 29463421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study.
    Ohfuji S; Ito K; Inoue M; Ishibashi M; Kumashiro H; Hirota Y; Kayano E; Ota N
    BMC Infect Dis; 2019 Jan; 19(1):95. PubMed ID: 30691396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.